| The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres S Simoens, G Dunselman, C Dirksen, L Hummelshoj, A Bokor, I Brandes, ... Human reproduction 27 (5), 1292-1299, 2012 | 1099 | 2012 |
| The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey AA De Graaff, TM D'hooghe, GAJ Dunselman, CD Dirksen, L Hummelshoj, ... Human reproduction 28 (10), 2677-2685, 2013 | 500 | 2013 |
| Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis F Rencz, L Gulácsi, M Péntek, N Wikonkál, P Baji, V Brodszky British journal of dermatology 175 (3), 561-571, 2016 | 223 | 2016 |
| Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries V Brodszky, P Baji, O Balogh, M Péntek The European Journal of Health Economics 15, 65-71, 2014 | 159 | 2014 |
| EQ-5D in central and Eastern Europe: 2000–2015 F Rencz, L Gulácsi, M Drummond, D Golicki, V Prevolnik Rupel, J Simon, ... Quality of Life Research 25, 2693-2710, 2016 | 137 | 2016 |
| Biosimilars for the management of rheumatoid arthritis: economic considerations L Gulacsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Pentek Expert review of clinical immunology 11 (sup1), 43-52, 2015 | 119 | 2015 |
| Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003 M Pentek, C Horváth, I Boncz, Z Falusi, E Tóth, A Sebestyen, I Májer, ... Osteoporosis international 19, 243-249, 2008 | 115 | 2008 |
| Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ... The European Journal of Health Economics 15, 111-119, 2014 | 93 | 2014 |
| A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016 | 90 | 2016 |
| Adherence to biologic DMARD therapies in rheumatoid arthritis T Koncz, M Pentek, V Brodszky, K Ersek, E Orlewska, L Gulacsi Expert opinion on biological therapy 10 (9), 1367-1378, 2010 | 83 | 2010 |
| Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe A Angelis, P Kanavos, J López-Bastida, R Linertová, J Oliva-Moreno, ... The European Journal of Health Economics 17, 31-42, 2016 | 80 | 2016 |
| The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries L Gulácsi, V Brodszky, P Baji, F Rencz, M Péntek Advances in therapy 34, 1128-1144, 2017 | 79 | 2017 |
| Cost-of-illness of patients with systemic sclerosis in a tertiary care centre T Minier, M Péntek, V Brodszky, A Ecseki, K Kárpáti, A Polgar, L Czirjak, ... Rheumatology 49 (10), 1920-1928, 2010 | 76 | 2010 |
| Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ... Value in Health 23 (9), 1235-1245, 2020 | 75 | 2020 |
| Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment V Brodszky, P Bálint, P Géher, L Hodinka, G Horváth, É Koó, M Péntek, ... Rheumatology international 30, 199-205, 2009 | 68 | 2009 |
| Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey M Moradi, F Rencz, V Brodszky, A Moradi, O Balogh, L Gulácsi Archives of Iranian medicine 18 (3), 0-0, 2015 | 67 | 2015 |
| Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a … V Brodszky, M Péntek, PV Bálint, P Géher, O Hajdu, L Hodinka, G Horvath, ... Scandinavian journal of rheumatology 39 (4), 303-309, 2010 | 67 | 2010 |
| Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients AK Poór, F Rencz, V Brodszky, L Gulácsi, Z Beretzky, B Hidvégi, P Holló, ... Quality of Life Research 26, 3409-3419, 2017 | 60 | 2017 |
| A detailed analysis of ‘not relevant’responses on the DLQI in psoriasis: potential biases in treatment decisions F Rencz, AK Poór, M Péntek, P Holló, S Kárpáti, L Gulácsi, A Szegedi, ... Journal of the European Academy of Dermatology and Venereology 32 (5), 783-790, 2018 | 58 | 2018 |
| Use of biologics for psoriasis in Central and Eastern European countries F Rencz, L Kemény, JZ Gajdácsi, W Owczarek, P Arenberger, GS Tiplica, ... Journal of the European Academy of Dermatology and Venereology 29 (11), 2222 …, 2015 | 58 | 2015 |
Prof. László Gulácsi, DScBudapest, Hungary, Óbuda UniversityVerified email at uni-obuda.hu
